GlassScriptPhysician profile
Safwat Shaker
NPI 1144246042
$7,573.11
in general payments reported to CMS, 2019-2025
50 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $830 · 2021: $1,140 · 2022: $1,002 · 2023: $1,355 · 2024: $942 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.37 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,819.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $866.17 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $847.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $480.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $436.27 | 2021-2024 | Gallant, Aveir, Freestyle Libre |
| Lilly USA, LLC | $295.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $277.19 | 2019-2023 | |
| Horizon Therapeutics Plc | $230.09 | 2021-2022 | |
| Amarin Pharma, INC. | $188.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $173.78 | 2019-2021 | |
| Pfizer INC. | $145.11 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $139.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.38 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $127.42 | 2021-2024 | Vraylar |
| Phathom Pharmaceuticals, INC. | $113.98 | 2024-2025 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safwat Shaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.